0001213900-20-016709.txt : 20200706 0001213900-20-016709.hdr.sgml : 20200706 20200706125833 ACCESSION NUMBER: 0001213900-20-016709 CONFORMED SUBMISSION TYPE: 15-15D PUBLIC DOCUMENT COUNT: 1 FILED AS OF DATE: 20200706 DATE AS OF CHANGE: 20200706 EFFECTIVENESS DATE: 20200706 FILER: COMPANY DATA: COMPANY CONFORMED NAME: XYNOMIC PHARMACEUTICALS HOLDINGS, INC. CENTRAL INDEX KEY: 0001697805 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 STATE OF INCORPORATION: D8 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 15-15D SEC ACT: 1934 Act SEC FILE NUMBER: 333-232598 FILM NUMBER: 201012799 BUSINESS ADDRESS: STREET 1: 609-610 21ST CENTURY TOWER STREET 2: 40 LIANGMAQIAO ROAD, CHAOYANG DISTRICT CITY: BEIJING STATE: F4 ZIP: 100016 BUSINESS PHONE: 9493506999 MAIL ADDRESS: STREET 1: 609-610 21ST CENTURY TOWER STREET 2: 40 LIANGMAQIAO ROAD, CHAOYANG DISTRICT CITY: BEIJING STATE: F4 ZIP: 100016 FORMER COMPANY: FORMER CONFORMED NAME: Bison Capital Acquisition Corp. DATE OF NAME CHANGE: 20170621 FORMER COMPANY: FORMER CONFORMED NAME: Bison Capital Acquisition Corp DATE OF NAME CHANGE: 20170209 15-15D 1 ea123857-1515d_xynomic.htm NOTICE OF TERMINATION OF REGISTRATION

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 15

CERTIFICATION AND NOTICE OF TERMINATION OF REGISTRATION UNDER SECTION 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR SUSPENSION OF DUTY TO FILE REPORTS UNDER SECTIONS 13 AND 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934.

Commission File Number 333-232598

XYNOMIC PHARMACEUTICALS HOLDINGS, INC.

(Exact name of registrant as specified in its charter)

Suite 3306, K. Wah Centre, 1010 Middle Huaihai Road,
Shanghai, China

(Address, including zip code, and telephone number, including area code, of registrant’s principal executive offices)

Common Stock, par value $0.0001 per share

Warrants (1)

(Title of each class of securities covered by this Form)

N/A

(Titles of all other classes of securities for which a duty to file reports under section 13(a) or 15(d) remains)

Please place an X in the box(es) to designate the appropriate rule provision(s) relied upon to terminate or suspend the duty to file reports:

Rule 12g-4(a)(1) ☐

Rule 12g-4(a)(2) ☐

Rule 12h-3(b)(1)(i) ☒

Rule 12h-3(b)(1)(ii) ☐

Rule 15d-6 ☐

Rule 15d-22(b) ☐

Approximate number of holders of record as of the certification or notice date: 18 holders of record of common stock, par value $0.0001 per share and 5 holders of record of warrants, as of the certification or notice date, respectively.

Pursuant to the requirements of the Securities Exchange Act of 1934, Xynomic Pharmaceuticals Holdings, Inc. has caused this certification/notice to be signed on its behalf by the undersigned duly authorized person.

Date: July 6, 2020

By:

/s/ Yinglin Mark Xu

Yinglin Mark Xu

Chairman of the Board,

Chief Executive Officer, and President

(1)

Each Whole warrant entitles the holder to purchase one share of common stock of Xynomic Pharmaceuticals Holdings, Inc. at a price of $11.50 per share, subject to adjustments set forth thereunder at any time commencing on May 15, 2019 and expiring on May 15, 2024.